The University of Southampton
University of Southampton Institutional Repository

Drug screening identifies tazarotene and bexarotene as therapeutic agents in Multiple Sulfatase Deficiency

Drug screening identifies tazarotene and bexarotene as therapeutic agents in Multiple Sulfatase Deficiency
Drug screening identifies tazarotene and bexarotene as therapeutic agents in Multiple Sulfatase Deficiency
Multiple sulfatase deficiency (MSD, MIM #272200) results from pathogenic variants in the SUMF1 gene that impair proper function of the formylglycine-generating enzyme (FGE). FGE is essential for the posttranslational activation of cellular sulfatases. MSD patients display reduced or absent sulfatase activities and, as a result, clinical signs of single sulfatase disorders in a unique combination. Up to date therapeutic options for MSD are limited and mostly palliative. We performed a screen of FDA-approved drugs using immortalized MSD patient fibroblasts. Recovery of arylsulfatase A activity served as the primary readout. Subsequent analysis confirmed that treatment of primary MSD fibroblasts with tazarotene and bexarotene, two retinoids, led to a correction of MSD pathophysiology. Upon treatment, sulfatase activities increased in a dose- and time-dependent manner, reduced glycosaminoglycan content decreased and lysosomal position and size normalized. Treatment of MSD patient derived induced pluripotent stem cells (iPSC) differentiated into neuronal progenitor cells (NPC) resulted in a positive treatment response. Tazarotene and bexarotene act to ultimately increase the stability of FGE variants. The results lay the basis for future research on the development of a first therapeutic option for MSD patients.
drug screening, formylglycine-generating enzyme, lysosomal disorder, retinoids, sulfatase-modifying factor 1
1757-4684
Schlotawa, Lars
36eef1d9-0624-4497-a35e-f564124b71dd
Tyka, Karolina
c23ce021-1567-470e-a15d-4c578e808791
Kettwig, Matthias
74e8b5d7-ee1a-428b-99b4-1d4f93654ae5
C Ahrens-Nicklas, Rebecca
ef5757cc-0087-48d7-a357-63e22a1f226d
Baud, Matthias G.J.
8752d519-3d33-43b6-9a77-ab731d410c2e
Berulava, Tea
e5f93e88-a122-45d9-8463-e224c211f227
Brunetti-Pierri, Nicola
9d72f71c-cb39-4026-bb9d-0c3d85703ab4
Gagne, Alyssa
6b7f13ec-d18e-4a52-9215-4784bc1ce9b2
M Herbst, Zackary
148f12e2-9ebf-4840-8568-8239b406e272
A Maguire, Jean
3e6c7ede-fcc3-4ecf-99a8-865af15dda06
Monfregola, Jlenia
8c8dbc5b-d9db-492d-85e5-91eb43535b22
Pena, Tonatiuh
9ea223fa-b32c-49b6-896a-36bd38c0a968
Radhakrishnan, Karthikeyan
863b81de-059e-4d69-93d6-7d64316ea332
Schröder, Sophie
57ee5847-803e-4b7b-98d5-2cbd3ec668a3
A Waxman, Elisa
c8f622fc-ed40-48cb-8b6c-f6c0ec9b3518
Ballabio, Andrea
1cf435be-4dba-4d0f-a67b-6cbb8469f7fb
Dierks, Thomas
03df62dc-6539-40a6-b8f3-4cc67486bbe0
Fischer, André
b1572ea8-d05f-4a94-b055-e06e80825e6d
L French, Deborah
d179758e-958d-4926-9948-626fafd6c188
Gelb, Michael H.
6b271def-03a1-4a78-ba1c-1220e522fd3e
Gärtner, Jutta
4e85846d-5ed7-4670-8a7f-bdfc4e9d572d
Schlotawa, Lars
36eef1d9-0624-4497-a35e-f564124b71dd
Tyka, Karolina
c23ce021-1567-470e-a15d-4c578e808791
Kettwig, Matthias
74e8b5d7-ee1a-428b-99b4-1d4f93654ae5
C Ahrens-Nicklas, Rebecca
ef5757cc-0087-48d7-a357-63e22a1f226d
Baud, Matthias G.J.
8752d519-3d33-43b6-9a77-ab731d410c2e
Berulava, Tea
e5f93e88-a122-45d9-8463-e224c211f227
Brunetti-Pierri, Nicola
9d72f71c-cb39-4026-bb9d-0c3d85703ab4
Gagne, Alyssa
6b7f13ec-d18e-4a52-9215-4784bc1ce9b2
M Herbst, Zackary
148f12e2-9ebf-4840-8568-8239b406e272
A Maguire, Jean
3e6c7ede-fcc3-4ecf-99a8-865af15dda06
Monfregola, Jlenia
8c8dbc5b-d9db-492d-85e5-91eb43535b22
Pena, Tonatiuh
9ea223fa-b32c-49b6-896a-36bd38c0a968
Radhakrishnan, Karthikeyan
863b81de-059e-4d69-93d6-7d64316ea332
Schröder, Sophie
57ee5847-803e-4b7b-98d5-2cbd3ec668a3
A Waxman, Elisa
c8f622fc-ed40-48cb-8b6c-f6c0ec9b3518
Ballabio, Andrea
1cf435be-4dba-4d0f-a67b-6cbb8469f7fb
Dierks, Thomas
03df62dc-6539-40a6-b8f3-4cc67486bbe0
Fischer, André
b1572ea8-d05f-4a94-b055-e06e80825e6d
L French, Deborah
d179758e-958d-4926-9948-626fafd6c188
Gelb, Michael H.
6b271def-03a1-4a78-ba1c-1220e522fd3e
Gärtner, Jutta
4e85846d-5ed7-4670-8a7f-bdfc4e9d572d

Schlotawa, Lars, Tyka, Karolina, Kettwig, Matthias, C Ahrens-Nicklas, Rebecca, Baud, Matthias G.J., Berulava, Tea, Brunetti-Pierri, Nicola, Gagne, Alyssa, M Herbst, Zackary, A Maguire, Jean, Monfregola, Jlenia, Pena, Tonatiuh, Radhakrishnan, Karthikeyan, Schröder, Sophie, A Waxman, Elisa, Ballabio, Andrea, Dierks, Thomas, Fischer, André, L French, Deborah, Gelb, Michael H. and Gärtner, Jutta (2023) Drug screening identifies tazarotene and bexarotene as therapeutic agents in Multiple Sulfatase Deficiency. EMBO Molecular Medicine, 15 (3), [e14837]. (doi:10.15252/emmm.202114837).

Record type: Article

Abstract

Multiple sulfatase deficiency (MSD, MIM #272200) results from pathogenic variants in the SUMF1 gene that impair proper function of the formylglycine-generating enzyme (FGE). FGE is essential for the posttranslational activation of cellular sulfatases. MSD patients display reduced or absent sulfatase activities and, as a result, clinical signs of single sulfatase disorders in a unique combination. Up to date therapeutic options for MSD are limited and mostly palliative. We performed a screen of FDA-approved drugs using immortalized MSD patient fibroblasts. Recovery of arylsulfatase A activity served as the primary readout. Subsequent analysis confirmed that treatment of primary MSD fibroblasts with tazarotene and bexarotene, two retinoids, led to a correction of MSD pathophysiology. Upon treatment, sulfatase activities increased in a dose- and time-dependent manner, reduced glycosaminoglycan content decreased and lysosomal position and size normalized. Treatment of MSD patient derived induced pluripotent stem cells (iPSC) differentiated into neuronal progenitor cells (NPC) resulted in a positive treatment response. Tazarotene and bexarotene act to ultimately increase the stability of FGE variants. The results lay the basis for future research on the development of a first therapeutic option for MSD patients.

Text
MSD drug screen TazBex manuscript_EMBO Mol Med editorial edits - Accepted Manuscript
Available under License Creative Commons Attribution.
Download (478kB)
Text
EMBO Mol Med - 2023 - Schlotawa - Drug screening identifies tazarotene and bexarotene as therapeutic agents in multiple (1) - Version of Record
Available under License Creative Commons Attribution.
Download (1MB)

More information

Accepted/In Press date: 9 January 2023
e-pub ahead of print date: 15 February 2023
Published date: 8 March 2023
Additional Information: © 2023 The Authors. Published under the terms of the CC BY 4.0 license.
Keywords: drug screening, formylglycine-generating enzyme, lysosomal disorder, retinoids, sulfatase-modifying factor 1

Identifiers

Local EPrints ID: 475519
URI: http://eprints.soton.ac.uk/id/eprint/475519
ISSN: 1757-4684
PURE UUID: 19fca9a7-7387-48b7-b39e-8655fcb9e6bf
ORCID for Matthias G.J. Baud: ORCID iD orcid.org/0000-0003-3714-4350

Catalogue record

Date deposited: 21 Mar 2023 17:33
Last modified: 28 Aug 2024 01:49

Export record

Altmetrics

Contributors

Author: Lars Schlotawa
Author: Karolina Tyka
Author: Matthias Kettwig
Author: Rebecca C Ahrens-Nicklas
Author: Tea Berulava
Author: Nicola Brunetti-Pierri
Author: Alyssa Gagne
Author: Zackary M Herbst
Author: Jean A Maguire
Author: Jlenia Monfregola
Author: Tonatiuh Pena
Author: Karthikeyan Radhakrishnan
Author: Sophie Schröder
Author: Elisa A Waxman
Author: Andrea Ballabio
Author: Thomas Dierks
Author: André Fischer
Author: Deborah L French
Author: Michael H. Gelb
Author: Jutta Gärtner

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×